Cargando…
Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy
SIMPLE SUMMARY: Cancer cachexia is an underestimated condition with huge impact on survival and quality of life for many cancer patients. Currently, there is no reliable diagnosis for this condition, particularly for cancer cachexia at an early stage. The aim of our study is to develop potential bio...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688504/ https://www.ncbi.nlm.nih.gov/pubmed/36428623 http://dx.doi.org/10.3390/cancers14225533 |
_version_ | 1784836285195616256 |
---|---|
author | Cao, Zhipeng Burvenich, Ingrid J. Zhao, Kening Senko, Clare Glab, Jason Fogliaro, Renee Liu, Zhanqi Jose, Irvin Puthalakath, Hamsa Hoogenraad, Nick J. Osellame, Laura D. Scott, Andrew M. |
author_facet | Cao, Zhipeng Burvenich, Ingrid J. Zhao, Kening Senko, Clare Glab, Jason Fogliaro, Renee Liu, Zhanqi Jose, Irvin Puthalakath, Hamsa Hoogenraad, Nick J. Osellame, Laura D. Scott, Andrew M. |
author_sort | Cao, Zhipeng |
collection | PubMed |
description | SIMPLE SUMMARY: Cancer cachexia is an underestimated condition with huge impact on survival and quality of life for many cancer patients. Currently, there is no reliable diagnosis for this condition, particularly for cancer cachexia at an early stage. The aim of our study is to develop potential biomarkers that can be used not only for diagnosing cancer cachexia but also evaluating potential anti-cachexia therapy such as anti-Fn14 mAb treatment. We identified several circulating biomarkers for cancer cachexia and confirmed that LCN2 is a promising biomarker for cancer cachexia in humans. These biomarkers could accelerate both diagnosis and clinical trials for cancer cachexia. ABSTRACT: Background: Developing therapies for cancer cachexia has not been successful to date, in part due to the challenges of achieving robust quantitative measures as a readout of patient treatment. Hence, identifying biomarkers to assess the outcomes of treatments for cancer cachexia is of great interest and important for accelerating future clinical trials. Methods: We established a novel xenograft model for cancer cachexia with a cachectic human PC3* cell line, which was responsive to anti-Fn14 mAb treatment. Using RNA-seq and secretomic analysis, genes differentially expressed in cachectic and non-cachectic tumors were identified and validated by digital droplet PCR (ddPCR). Correlation analysis was performed to investigate their impact on survival in cancer patients. Results: A total of 46 genes were highly expressed in cachectic PC3* tumors, which were downregulated by anti-Fn14 mAb treatment. High expression of the top 10 candidates was correlated with low survival and high cachexia risk in different cancer types. Elevated levels of LCN2 were observed in serum samples from cachectic patients compared with non-cachectic cancer patients. Conclusion: The top 10 candidates identified in this study are candidates as potential biomarkers for cancer cachexia. The diagnostic value of LCN2 in detecting cancer cachexia is confirmed in patient samples. |
format | Online Article Text |
id | pubmed-9688504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96885042022-11-25 Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy Cao, Zhipeng Burvenich, Ingrid J. Zhao, Kening Senko, Clare Glab, Jason Fogliaro, Renee Liu, Zhanqi Jose, Irvin Puthalakath, Hamsa Hoogenraad, Nick J. Osellame, Laura D. Scott, Andrew M. Cancers (Basel) Article SIMPLE SUMMARY: Cancer cachexia is an underestimated condition with huge impact on survival and quality of life for many cancer patients. Currently, there is no reliable diagnosis for this condition, particularly for cancer cachexia at an early stage. The aim of our study is to develop potential biomarkers that can be used not only for diagnosing cancer cachexia but also evaluating potential anti-cachexia therapy such as anti-Fn14 mAb treatment. We identified several circulating biomarkers for cancer cachexia and confirmed that LCN2 is a promising biomarker for cancer cachexia in humans. These biomarkers could accelerate both diagnosis and clinical trials for cancer cachexia. ABSTRACT: Background: Developing therapies for cancer cachexia has not been successful to date, in part due to the challenges of achieving robust quantitative measures as a readout of patient treatment. Hence, identifying biomarkers to assess the outcomes of treatments for cancer cachexia is of great interest and important for accelerating future clinical trials. Methods: We established a novel xenograft model for cancer cachexia with a cachectic human PC3* cell line, which was responsive to anti-Fn14 mAb treatment. Using RNA-seq and secretomic analysis, genes differentially expressed in cachectic and non-cachectic tumors were identified and validated by digital droplet PCR (ddPCR). Correlation analysis was performed to investigate their impact on survival in cancer patients. Results: A total of 46 genes were highly expressed in cachectic PC3* tumors, which were downregulated by anti-Fn14 mAb treatment. High expression of the top 10 candidates was correlated with low survival and high cachexia risk in different cancer types. Elevated levels of LCN2 were observed in serum samples from cachectic patients compared with non-cachectic cancer patients. Conclusion: The top 10 candidates identified in this study are candidates as potential biomarkers for cancer cachexia. The diagnostic value of LCN2 in detecting cancer cachexia is confirmed in patient samples. MDPI 2022-11-10 /pmc/articles/PMC9688504/ /pubmed/36428623 http://dx.doi.org/10.3390/cancers14225533 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cao, Zhipeng Burvenich, Ingrid J. Zhao, Kening Senko, Clare Glab, Jason Fogliaro, Renee Liu, Zhanqi Jose, Irvin Puthalakath, Hamsa Hoogenraad, Nick J. Osellame, Laura D. Scott, Andrew M. Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy |
title | Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy |
title_full | Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy |
title_fullStr | Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy |
title_full_unstemmed | Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy |
title_short | Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy |
title_sort | identification of potential biomarkers for cancer cachexia and anti-fn14 therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688504/ https://www.ncbi.nlm.nih.gov/pubmed/36428623 http://dx.doi.org/10.3390/cancers14225533 |
work_keys_str_mv | AT caozhipeng identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT burvenichingridj identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT zhaokening identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT senkoclare identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT glabjason identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT fogliarorenee identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT liuzhanqi identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT joseirvin identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT puthalakathhamsa identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT hoogenraadnickj identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT osellamelaurad identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy AT scottandrewm identificationofpotentialbiomarkersforcancercachexiaandantifn14therapy |